JenaValve Technology, Inc.

JenaValve Technology, Inc. is a medical device company dedicated to developing innovative transcatheter heart valve (THV) solutions for the treatment of patients with heart valve disease. They specialize in the treatment of aortic regurgitation (AR), a condition where the aortic valve doesn't close properly, leading to a backflow of blood. Their flagship product is the Trilogy™ THV System, a TAVR system designed to treat patients with symptomatic, severe AR and symptomatic, severe aortic stenosis (AS) who are at high surgical risk.

JenaValve is a global company with headquarters in Irvine, California, and offices in Leeds, United Kingdom, and Munich, Germany. Their commitment to research and development is evident in the ALIGN-AR pivotal trial, which evaluated the safety and efficacy of the Trilogy THV System in high-risk patients with symptomatic, severe AR. The company is backed by a strong investor syndicate, including Bain Capital Life Sciences, Andera Partners, and Rosetta Capital.

JenaValve Technology, Inc. is a global medical device company dedicated to developing innovative solutions for the treatment of severe aortic regurgitation (AR) and severe aortic stenosis (AS). The company's mission is to redefine the treatment of these conditions by providing minimally invasive, transcatheter aortic valve replacement (TAVR) options that improve patient outcomes and quality of life. Their flagship product, the Trilogy™ Transcatheter Heart Valve (THV) System, is specifically designed to address the needs of high-risk patients who are not eligible for traditional open-heart surgery.

JenaValve fosters a culture of teamwork, innovation, and integrity. They emphasize the importance of their core values, including a sacred trust with patients and physicians, enabling life, and making a difference every day. This commitment to a shared purpose is evident in the testimonials of their employees, who express pride in their work and the impact it has on the lives of patients. Their diverse and talented team is driven by a passion for transforming the future of aortic regurgitation treatment.

JenaValve is committed to fostering a diverse, equitable, and inclusive workplace where all employees feel valued, respected, and empowered to contribute their unique talents. They strive to create a culture that reflects the diversity of the communities they serve, embracing individuals from all backgrounds, identities, and perspectives. JenaValve is dedicated to promoting equity through fair and transparent hiring practices, inclusive leadership development, and accessible opportunities for advancement. They are actively working to build an inclusive environment where all employees feel a sense of belonging and can thrive.